Neurogene (NASDAQ:NGNE - Get Free Report)'s stock had its "outperform" rating reissued by research analysts at William Blair in a research note issued on Tuesday,RTT News reports.
Other analysts have also issued research reports about the company. HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of Neurogene in a report on Tuesday. Stifel Nicolaus lifted their price objective on Neurogene from $44.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday, November 12th. Robert W. Baird lifted their price objective on Neurogene from $54.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday, November 12th. BMO Capital Markets cut their price objective on Neurogene from $65.00 to $60.00 and set an "outperform" rating for the company in a report on Tuesday, November 12th. Finally, Leerink Partners lifted their price objective on Neurogene from $45.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $63.33.
Read Our Latest Stock Analysis on Neurogene
Neurogene Stock Down 13.1 %
Shares of Neurogene stock traded down $2.59 on Tuesday, reaching $17.23. The company's stock had a trading volume of 1,231,822 shares, compared to its average volume of 154,324. The firm's fifty day simple moving average is $46.38 and its two-hundred day simple moving average is $39.96. Neurogene has a 52 week low of $12.49 and a 52 week high of $74.49.
Institutional Trading of Neurogene
Several hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its holdings in Neurogene by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company's stock valued at $1,272,000 after purchasing an additional 741 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Neurogene by 192.8% in the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company's stock valued at $91,000 after acquiring an additional 1,429 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of Neurogene in the second quarter worth about $55,000. SG Americas Securities LLC purchased a new stake in shares of Neurogene in the first quarter worth about $120,000. Finally, Baker BROS. Advisors LP lifted its position in shares of Neurogene by 0.6% in the first quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company's stock worth $23,211,000 after buying an additional 2,499 shares in the last quarter. Institutional investors own 52.37% of the company's stock.
About Neurogene
(
Get Free Report)
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Articles
Before you consider Neurogene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.
While Neurogene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
